Work

Amyloid‐associated increases in longitudinal report of subjective cognitive complaints

Year: 2018

Type: article

Study design: Observational Study

Abstract: Introduction To investigate whether baseline subjective cognitive complaints (SCCs) predict longitudinal decline on neuropsychological testing and whether SCC increases longitudinally, in the setting of high levels of amyloid burden. Methods Two hundred seventy‐nine clinically normal older participants (mean age = 73.7 ± 6.1 years) from the Harvard Aging Brain Study, a cohort of community‐dwelling individuals, were followed longitudinally (4.27 ± 1.35 years) with annual subjective memory questionnaires and neuropsychological assessment. 11 C Pittsburgh compound‐B positron emission tomography was used to measure cortical amyloid and to classify status (Aβ+/Aβ−) at baseline. Results Higher baseline SCC predicted more rapid cognitive decline on neuropsychological measures among those with elevated amyloid (t = −2.18, P < .0001). In addition, longitudinal report of SCC significantly increased over time, with SCC progression most pronounced among Aβ+ individuals (t = 2.24, P = .0005). Discussion SCC may inform risk for future cognitive decline and track progression of self‐perceived decline, particularly in those along the AD trajectory, providing potentially important indicators of clinical meaningfulness in AD prevention trials.

Source: Alzheimer s & Dementia Translational Research & Clinical Interventions

DOI: 10.1016/j.trci.2018.08.005

Authors: Rebecca E. Amariglio, Rachel F. Buckley, Elizabeth C. Mormino, Gad A. Marshall, Keith A. Johnson, Dorene M. Rentz, Reisa A. Sperling

Institutions: Brigham and Women's Hospital, Harvard University, Massachusetts General Hospital, The University of Melbourne, Florey Institute of Neuroscience and Mental Health, Stanford Medicine, Stanford University

Language: English

Topic: Dementia and Cognitive Impairment Research

Subfield: Psychiatry and Mental health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,540

Funders: Alzheimer's Association, Eli Lilly and Company, Biogen, Eisai, H. Lundbeck A/S, Grifols, National Institutes of Health, Genentech, National Health and Medical Research Council, National Institute on Aging, National Institute of Biomedical Imaging and Bioengineering

Awards: G104586243, G2080581370, Vascular Dysfunction in Cerebral Amyloid Angiopathy, G3652633055, What can tau deposition tell us about the appearance of subjective and objective cognitive decline in older adults?, The Role of Alzheimer's-associated Abeta in POD and POCD, Mentoring Imaging Research in Early AD, Examining the trajectory of Subjective Cognitive Decline in preclinical AD, Alzheimer's Disease Neuroimaging Initiative, Evolution of memory related fMRI activation over the course of MCI and AD, Optimizing measures of subjective and objective decline in preclinical AD, Characterizing the Evolution of Amyloid Deposition in Normal Elderly, MR-assisted PET data optimization for neuroimaging studies, Massachusetts Alzheimer's Disease Research Center, G7855923974, Alzheimer's Disease Cooperative Study, Dominantly Inherited Alzheimer Network, Influence of genetic risk factors on biomarkers and cognitive decline in preclinical AD, Neural Processes Underlying Cognitive Aging, G9000121663, Impact of Amyloid and Tau on the Aging Brain: The Harvard Aging Brain Study

OpenAlex ID: W2889724547

FWCI: 9.573

Cites: 43

Cited by: 80

Related to: 10